NASDAQ: CRNX
Crinetics Pharmaceuticals Inc Stock

$31.77-0.40 (-1.24%)
Updated Jun 13, 2025
CRNX Price
$31.77
Fair Value Price
$0.58
Market Cap
$2.98B
52 Week Low
$24.10
52 Week High
$62.53
P/E
-8.34x
P/B
2.37x
P/S
4,108.74x
PEG
N/A
Dividend Yield
N/A
Revenue
$760.00k
Earnings
-$328.25M
Gross Margin
100%
Operating Margin
-43,191.05%
Profit Margin
-43,191.1%
Debt to Equity
0.09
Operating Cash Flow
-$262M
Beta
1.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CRNX Overview

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine CRNX's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
CRNX
Ranked
#339 of 464

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important CRNX news, forecast changes, insider trades & much more!

CRNX News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CRNX ($31.77) is overvalued by 5,366.6% relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRNX ($31.77) is not significantly undervalued (5,366.6%) relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRNX due diligence checks available for Premium users.

Valuation

CRNX fair value

Fair Value of CRNX stock based on Discounted Cash Flow (DCF)

Price
$31.77
Fair Value
$0.58
Overvalued by
5,366.60%
CRNX ($31.77) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRNX ($31.77) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CRNX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-8.34x
Industry
-108.97x
Market
31.36x

CRNX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.37x
Industry
4.66x
CRNX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CRNX's financial health

Profit margin

Revenue
$361.0k
Net Income
-$96.8M
Profit Margin
-26,807.2%
CRNX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CRNX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.4B
Liabilities
$107.3M
Debt to equity
0.09
CRNX's short-term assets ($1.29B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRNX's short-term assets ($1.29B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRNX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$88.5M
Investing
-$86.0M
Financing
$4.4M
CRNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CRNX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
CRNXD$2.98B-1.24%-8.34x2.37x
VKTXF$2.93B-8.75%-22.68x3.46x
KYMRC$3.06B-0.70%-15.10x3.89x
SRRKD$3.08B-2.61%-12.78x9.86x
CPRXA$2.87B-3.13%14.26x3.61x

Crinetics Pharmaceuticals Stock FAQ

What is Crinetics Pharmaceuticals's quote symbol?

(NASDAQ: CRNX) Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol CRNX. Crinetics Pharmaceuticals stock quotes can also be displayed as NASDAQ: CRNX.

If you're new to stock investing, here's how to buy Crinetics Pharmaceuticals stock.

What is the 52 week high and low for Crinetics Pharmaceuticals (NASDAQ: CRNX)?

(NASDAQ: CRNX) Crinetics Pharmaceuticals's 52-week high was $62.53, and its 52-week low was $24.10. It is currently -49.19% from its 52-week high and 31.83% from its 52-week low.

How much is Crinetics Pharmaceuticals stock worth today?

(NASDAQ: CRNX) Crinetics Pharmaceuticals currently has 93,680,130 outstanding shares. With Crinetics Pharmaceuticals stock trading at $31.77 per share, the total value of Crinetics Pharmaceuticals stock (market capitalization) is $2.98B.

Crinetics Pharmaceuticals stock was originally listed at a price of $24.51 in Jul 18, 2018. If you had invested in Crinetics Pharmaceuticals stock at $24.51, your return over the last 6 years would have been 29.62%, for an annualized return of 4.42% (not including any dividends or dividend reinvestments).

How much is Crinetics Pharmaceuticals's stock price per share?

(NASDAQ: CRNX) Crinetics Pharmaceuticals stock price per share is $31.77 today (as of Jun 13, 2025).

What is Crinetics Pharmaceuticals's Market Cap?

(NASDAQ: CRNX) Crinetics Pharmaceuticals's market cap is $2.98B, as of Jun 16, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Crinetics Pharmaceuticals's market cap is calculated by multiplying CRNX's current stock price of $31.77 by CRNX's total outstanding shares of 93,680,130.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.